Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified April 2017 by National Cancer Institute (NCI)
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: November 30, 2016
Last updated: April 20, 2017
Last verified: April 2017
This phase II trial studies how well talimogene laherparepvec works and nivolumab in treating patients with lymphomas that do not responded to treatment or non-melanoma skin cancers that have spread to other places in the body or do not responded to treatment. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Monoclonal antibodies, such as nivolumab, may block a protein needed by tumor cells to grow and spread. Giving talimogene laherparepvec and nivolumab may work better in treating patients with lymphomas or non-melanoma skin cancers.

Condition Intervention Phase
Adenoid Cystic Carcinoma
Adnexal Carcinoma
Apocrine Carcinoma
Eccrine Porocarcinoma
Extraocular Cutaneous Sebaceous Carcinoma
Malignant Sweat Gland Neoplasm
Merkel Cell Carcinoma
Microcystic Adnexal Carcinoma
NK-Cell Lymphoma, Unclassifiable
Non-Melanomatous Lesion
Paget Disease
Papillary Adenocarcinoma
Primary Cutaneous Mucinous Carcinoma
Refractory Anaplastic Large Cell Lymphoma
Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma
Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Refractory Mycosis Fungoides
Refractory T-Cell Non-Hodgkin Lymphoma
Sezary Syndrome
Signet Ring Cell Carcinoma
Skin Basal Cell Carcinoma
Skin Basosquamous Cell Carcinoma
Skin Squamous Cell Carcinoma
Squamous Cell Carcinoma of Unknown Primary Origin
Stage III Skin Cancer
Stage IV Skin Cancer
Sweat Gland Carcinoma
Vulvar Squamous Cell Carcinoma
Other: Laboratory Biomarker Analysis
Biological: Nivolumab
Biological: Talimogene Laherparepvec
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase II Study of T-VEC Followed by T-VEC + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Best overall response rate to talimogene laherparepvec alone as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 [ Time Frame: Up to 1 year ]
    Arm assignment is based on tumor type: Merkel cell carcinoma, squamous cell carcinoma, other non-melanoma skin cancers, and refractory T cell lymphomas and NK cell lymphomas. If at least 4 responses were observed in an arm (observed RR = 4/17 or 23.5%), T-VEC would be considered promising in that tumor type. Between-arm comparisons will not be performed

Secondary Outcome Measures:
  • Best overall response rate to talimogene laherparepvec and nivolumab combination therapy as assessed by RECIST version 1.1 [ Time Frame: Up to 1 year ]
  • Durable response rate defined as complete response or partial response lasting >= 6 months [ Time Frame: Up to 1 year ]
  • Frequency of curative surgery (unresectable lesion becomes resectable) [ Time Frame: Up to 1 year ]
  • Incidence of adverse events assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 [ Time Frame: Up to week 24 ]
  • Overall survival [ Time Frame: At 1 year ]
  • Overall survival [ Time Frame: At 2 years ]
  • Progression free survival [ Time Frame: From start of treatment to time of progression or death, whichever occurs first, assessed at 1 year ]
  • Progression free survival [ Time Frame: From start of treatment to time of progression or death, whichever occurs first, assessed at 2 years ]
  • Response rate by cancer type assessed by RECIST version 1.1 [ Time Frame: Up to 1 year ]
  • Response rate of injected lesions assessed by RECIST version 1.1 [ Time Frame: Up to 1 year ]
  • Response rate of non-injected lesions assessed by RECIST version 1.1 [ Time Frame: Up to 1 year ]

Other Outcome Measures:
  • Biomarker analysis of %PD-L1, flow cytometry for HVEM, NECTIN1/2, and IDO, Tryptophan and L-kynurenine, cytokine levels, Nanostring, number of non-synonymous mutations, and % TCR clonality [ Time Frame: Up to 1 year ]
    Will be analyzed using descriptive statistics. Logistic regression of response rate on the variable will be performed.

  • Biomarker analysis of HSV status, Merkel cell polyomavirus status, and PD-L1 status [ Time Frame: Up to 1 year ]
    Will be analyzed using descriptive statistics. Test of proportions and logistic regression will be performed.

  • Biomarker analysis of necrosis and Nanostring [ Time Frame: Up to 1 year ]
    Will be analyzed using descriptive statistics. Logistic regression of response rate on the variable will be performed.

  • Change in HSV serostatus assessed in blood specimens [ Time Frame: Baseline to week 6 ]
    Will be analyzed using descriptive statistics. A test of proportions will be performed.

Estimated Enrollment: 68
Anticipated Study Start Date: August 4, 2017
Estimated Study Completion Date: January 31, 2019
Estimated Primary Completion Date: January 31, 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (talimogene laherparepvec, nivolumab)
Patients receive talimogene laherparepvec IT on day 1. Patients without response at week 12, may also receive nivolumab IV over 60 minutes on day 1. Courses repeat every 21 or 14 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
Other: Laboratory Biomarker Analysis
Correlative studies
Biological: Nivolumab
Given IV
Other Names:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
Biological: Talimogene Laherparepvec
Given IT
Other Names:
  • ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene
  • Imlygic
  • JS1 34.5-hGMCSF 47- pA-
  • T-VEC

Detailed Description:


I. To determine the frequency of patients responding (response rate) to talimogene laherparepvec (T-VEC) monotherapy.


I. To determine the local response rate to T-VEC in injected tumors. II. To determine the response rate to T-VEC + nivolumab (NIVO). III. To identify potential pre-treatment and on-treatment correlative biomarkers of local and systemic immune response.


Patients receive talimogene laherparepvec intratumorally (IT) on day 1. Patients without response at week 12, may also receive nivolumab intravenously (IV) over 60 minutes on day 1. Courses repeat every 21 or 14 days for up to 1 year in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 12 weeks for 3 years.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have histologic or cytologic diagnosis of non-melanoma skin cancer (NMSC) or lymphomas other than B-cell lymphomas; as both of those terms are categories rather than specific diagnoses, specific guidance on eligible tumor types is provided below
  • Included tumor types

    • T cell and NK cell lymphomas, including, but not limited to: cutaneous T-cell lymphomas (CTCL), mycosis fungoides (MF), Sezary syndrome (SS), peripheral T-cell lymphoma (PTCL), ALK-positive and ALK-negative anaplastic large cell lymphoma (ALCL), and NK-cell lymphomas
    • Merkel cell carcinoma
    • Squamous cell carcinoma of the skin, including keratoacanthomas, vulvar squamous carcinoma, and mixed histology tumors, such as basosquamous carcinoma, and squamous cell carcinoma of unknown primary consistent with skin origin
    • Basal cell carcinoma
    • Malignant sweat gland tumors, including porocarcinoma, hidradenocarcinoma, spiradenocarcinoma, cylindrocarcinoma, microcystic adnexal carcinoma and related entities, squamoid eccrine ductal carcinoma, cutaneous adenoid cystic carcinoma, digital papillary adenocarcinoma, primary cutaneous mucinous carcinoma, endocrine mucin-producing sweat gland carcinoma, primary cutaneous signet ring cell carcinoma, cutaneous apocrine gland carcinoma, and extraocular sebaceous carcinoma
    • Adnexal carcinoma
    • Trichilemmal carcinoma
    • Paget's disease
    • Any other rare tumor of the skin with approval of principle investigator (PI)
  • Patients with T cell and natural killer (NK) cell lymphomas must be refractory to, be intolerant of, have relapsed following, or have refused all standard life-prolonging therapies
  • Patients with non-melanoma skin cancers (NMSC) must have advanced or refractory tumors

    • Advanced/unresectable is defined by at least 1 of the following criteria: tumors 2 cm or more, tumors considered unresectable, tumors invading deep tissues such as muscle, cartilage or bone, tumors showing perineural invasion, and/or tumors metastatic to loco-regional lymph nodes and/or distant sites
    • Refractory is defined by persistent or recurrent tumor despite prior therapy consisting of at least 1 of the following: surgery, radiation therapy, intralesional therapy, topical therapy, or systemic therapy
  • Subjects must have at least 1 cutaneous, subcutaneous, or nodal lesion that is suitable for intralesional injection, with or without the use of ultrasound; lesions in mucosal surfaces (periocular, nasal, etc) are not eligible for injection because the area cannot be properly contained with an occlusive dressing
  • Subjects must have radiographically or clinically measurable disease, defined as at least one lesion that is >= 10 mm in diameter in at least 1 dimension, or an aggregate of lesions that measures >= 10 mm in diameter in at least 1 dimension
  • Subjects must be able and willing to undergo serial biopsies of injected lesion(s) and, when applicable and clinically feasible, non-injected lesions
  • Subjects who are on immunosuppressive medications must be stable on their regimen for > 60 days prior to study entry
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
  • Absolute neutrophil count (ANC) >= 1.2 x 10^9/L
  • Hemoglobin >= 9 g/dL without transfusion in the preceding 7 days
  • Platelets >= 75 x 10^9/L
  • Albumin >= 2.5 g/dL
  • Serum total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (patients with Gilbert's syndrome with a total bilirubin < 3.0 mg/dL)
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN
  • Serum creatinine =< 1.5 mg/dL OR calculated creatinine clearance (Cockroft-Gault formula) >= 50 mL/min OR 24-hour urine creatinine clearance >= 50 mL/min
  • Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< 1.5 x institutional UNL, unless the subject is on anticoagulant therapy; (if the subject is receiving anticoagulant therapy, PT, and activated PTT (aPTT) must be within therapeutic range of intended use of anticoagulants)
  • Women of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence from heterosexual intercourse) prior to study entry, during the study participation, and for three months after the last dose of the drug; WOCBP must have a negative serum pregnancy test within 14 days prior to randomization and agree to use effective contraception throughout the treatment period and for 3 months after the last dose of study treatment; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Excluded tumor types

    • Melanoma
    • Bone sarcomas
    • Soft tissue sarcomas, including angiosarcoma, primary cutaneous leiomyosarcoma, dermatofibrosarcoma protruberans
    • Leukemias
    • Myeloid sarcoma, leukemia cutis, and chloroma
    • Hodgkin's lymphoma
    • B cell lymphoma
  • Patients who have had systemic therapy or radiotherapy within 3 weeks prior to the first dose of study therapy
  • Untreated central nervous system (CNS) involvement
  • Previous treatment with T-VEC or other herpes virus based therapy; (prior therapy with checkpoint inhibitors and/or other immunotherapy is allowed)
  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1 excepting alopecia, peripheral sensory neuropathy, and stable endocrine insufficiencies such as thyroid and adrenal insufficiency)
  • Second primary malignancy, only if it would affect the safety of the treatment or the subject's ability to complete study-related procedures
  • History or evidence of active autoimmune disease (e.g., pneumonitis, glomerulonephritis, vasculitis, or other); or history of active autoimmune disease that has required systemic treatment (i.e., use of corticosteroids, immunosuppressive drugs or biological agents used for treatment of autoimmune diseases) within 2 months of enrollment; (replacement therapy [e.g., thyroxine for hypothyroidism, insulin for diabetes or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency] is not considered a form of systemic treatment for autoimmune disease)
  • Evidence of clinically significant immunosuppression such as the following:

    • Primary immunodeficiency state such as severe combined immunodeficiency disease
    • Receiving systemic immunosuppressive therapy including prednisone > 10 mg per day (or equivalent), tacrolimus, everolimus, sirolimus, mycophenolate mofetil, etanercept, infliximab, etc.
    • Patients currently receiving extracorporeal photopheresis for treatment of graft versus host disease (GVHD) are excluded
    • Notes: Oral steroid doses =< 10 mg/day of prednisone (or equivalent) are not considered immunosuppressive and are permitted; inhaled and intraarticular corticosteroids are permitted
  • Active herpetic skin lesions or prior complications of herpetic infection (e.g., herpetic keratitis or encephalitis)
  • Viral infections requiring intermittent or chronic systemic (intravenous or oral) treatment with an antiherpetic drug (e.g., acyclovir), other than intermittent topical use
  • Other viral infections:

    • Known to have acute or chronic active hepatitis B or hepatitis C infection
    • Known to have human immunodeficiency virus (HIV) infection
    • Prior therapy with viral-based tumor vaccine
    • Received live vaccine within 28 days prior to enrollment
  • Subject who is unwilling to minimize exposure with his/her blood or other body fluids to individuals who are at higher risks for human herpesvirus 1 (HSV-1) induced complications such as immunosuppressed individuals, individuals known to have HIV infection, pregnant women, or children under the age of 1 year, during T-VEC treatment and through 30 days after the last dose of T-VEC
  • Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Female subject is pregnant or breast-feeding, or planning to become pregnant during study treatment and through 3 months after the last dose of T-VEC; female subject of childbearing potential who is unwilling to use acceptable method(s) of effective contraception during study treatment and through 3 months after the last dose of T-VEC; sexually active subjects and their partners unwilling to use male or female latex condom to avoid potential viral transmission during sexual contact while on treatment and within 30 days after treatment with T-VEC
  • HIV-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
  • Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to T-VEC or any of its components or nivolumab, or history of severe hypersensitivity reaction to any monoclonal antibody
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02978625

United States, New Jersey
Rutgers University - Cancer Institute of New Jersey LAO Not yet recruiting
New Brunswick, New Jersey, United States, 08903
Contact: Ann (Annie) W. Silk    732-235-8675   
Principal Investigator: Ann (Annie) W. Silk         
Sponsors and Collaborators
National Cancer Institute (NCI)
Principal Investigator: Ann (Annie) Silk Rutgers University - Cancer Institute of New Jersey LAO
  More Information

Responsible Party: National Cancer Institute (NCI) Identifier: NCT02978625     History of Changes
Other Study ID Numbers: NCI-2016-01804
NCI-2016-01804 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
10057 ( Other Identifier: Rutgers University - Cancer Institute of New Jersey LAO )
10057 ( Other Identifier: CTEP )
P30CA072720 ( US NIH Grant/Contract Award Number )
UM1CA186716 ( US NIH Grant/Contract Award Number )
Study First Received: November 30, 2016
Last Updated: April 20, 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Carcinoma, Squamous Cell
Carcinoma, Basal Cell
Carcinoma, Adenoid Cystic
Carcinoma, Merkel Cell
Carcinoma, Basosquamous
Carcinoma, Skin Appendage
Carcinoma, Signet Ring Cell
Carcinoma, Neuroendocrine
Neoplasms, Cystic, Mucinous, and Serous
Lymphoma, Non-Hodgkin
Mycosis Fungoides
Lymphoma, T-Cell
Sezary Syndrome
Lymphoma, T-Cell, Cutaneous
Lymphoma, Large-Cell, Anaplastic
Skin Neoplasms
Neoplasms, Unknown Primary
Lymphoma, T-Cell, Peripheral
Sweat Gland Neoplasms
Muir-Torre Syndrome
Adenocarcinoma, Sebaceous
Eccrine Porocarcinoma
Adenocarcinoma, Mucinous
Adenocarcinoma, Papillary
Neoplasms by Histologic Type processed this record on April 24, 2017